14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of 1AD.AX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Friday for AdAlta Limited stock after losing 0%
(Updated on May 17, 2024)

Sell candidate since May 03, 2024 Loss -11.11% PDF

No changes to the price of AdAlta Limited stock on the last trading day (Friday, 17th May 2024). During the last trading day the stock fluctuated 4.35% from a day low at $0.0230 to a day high of $0.0240. The price has fallen in 5 of the last 10 days and is down by -11.11% for this period.

The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 9.23% during the next 3 months and, with a 90% probability hold a price between $0.0234 and $0.0346 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

1AD.AX Signals & Forecast

There are mixed signals in the stock today. The AdAlta Limited stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $0.0268. On a fall, the stock will find some support from the short-term average at $0.0237. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on Friday, April 26, 2024, and so far it has fallen -22.58%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for AdAlta Limited stock

AdAlta Limited finds support from accumulated volume at $0.0230 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0010 between high and low, or 4.35%. For the last week the stock has had daily average volatility of 7.83%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (1AD.AX) For The Upcoming Trading Day Of Monday 20th

For the upcoming trading day on Monday, 20th we expect AdAlta Limited to open at $0.0237, and during the day (based on 14 day Average True Range), to move between $0.0219 and $0.0261, which gives a possible trading interval of +/-$0.0021 (+/-8.64%) up or down from last closing price. If AdAlta Limited takes out the full calculated possible swing range there will be an estimated 17.28% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $0.0250 (4.17%) than the support at $0.0230 (4.17%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is AdAlta Limited stock A Buy?

AdAlta Limited holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -3.376 Sell Candidate Unchanged

Predicted Opening Price for AdAlta Limited of Monday, May 20, 2024

Fair opening price May 20, 2024 Current price
$0.0237 ( 1.39%) $0.0240

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for 1AD.AX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 0.0247 2.78 %
R2 0.0243 1.19 %
R1 0.0240 0.203 %
Current price: 0.0240
Support S1 0.0233 -2.98 %
S2 0.0230 -3.96 %
S3 0.0227 -5.56 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0.0290 20.83 %
R2 0.0270 12.50 %
R1 0.0250 4.17 %
Current price 0.0240
Support S1 0.0230 -4.17%
S2 0.0220 -8.33%
S3 0.0190 -20.83%

FAQ

What is the symbol for AdAlta Limited Stock and on which exchange is it traded?
The symbol for AdAlta Limited is 1AD.AX and it is traded on the ASX (Australian Securities Exchange).

Should I buy or sell AdAlta Limited Stock?
AdAlta Limited holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy AdAlta Limited Stock?
AdAlta Limited Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy AdAlta Limited Stock.

What's the current price of AdAlta Limited Stock?
As of the end of day on the May 17, 2024, the price of an AdAlta Limited (1AD.AX) share was $0.0240.

What is the 52-week high and low for AdAlta Limited Stock?
The 52-week high for AdAlta Limited Stock is $0.0480 and the 52-week low is $0.0170.

What is the market capitalization of AdAlta Limited Stock?
As of the May 17, 2024, the market capitalization of AdAlta Limited is 12.796M.

When is the next earnings date for AdAlta Limited?
The upcoming earnings date for AdAlta Limited is Aug 24, 2024.
Click to get the best stock tips daily for free!

About AdAlta Limited

AdAlta Limited AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products agai... 1AD.AX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT